Compare Global Payments Inc (GPN) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Global Payments Inc vs Sana Biotechnology Inc — how do they compare? Global Payments Inc trades at $82.55 (market cap $21.46B), while Sana Biotechnology Inc trades at $2.8 (market cap $836.71M). The key difference: Global Payments Inc is far larger — about 25.6× Sana Biotechnology Inc's market cap, and Global Payments Inc pays a 1.23% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Global Payments Inc for 50 Days and Sana Biotechnology Inc for 23 Days on average.
| GPN | SANA | |
|---|---|---|
Market Cap | $21.46B | $836.71M |
Volume | 1,482,600 | 4,507,444 |
Sector | Financials | Health |
52-Week High | $94.83 | $5.92 |
52-Week Low | $62.47 | $2.68 |
Typical Hold Time | 50 Days | 23 Days |
Enterprise Value | $39.60B | $749.96M |
Dividend Yield | 1.23% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Global Payments (GPN) trades at $82.20, up 1.38% with neutral technical signals. The stock shows strong earnings momentum with three consecutive quarterly beats, though faces profitability challenges with negative net margins. Recent developments include the Genius platform rollout and Worldpay integration driving growth potential. Valuation metrics show a P/E of 38.43 and P/B below book value at 0.93, while analyst consensus remains bullish with a $102.75 price target.
Investment outlook balances growth catalysts from digital payment expansion against rising costs and competitive pressures. The 24% upside to consensus target offers potential reward, but investors must weigh debt levels increasing to 41.57% debt-to-asset ratio and projected 2026 net loss against strategic initiatives. Near-term performance hinges on Q3 earnings delivery and Genius adoption metrics.
SANA Biotechnology trades at $2.84, up 4.41% today, while showing bearish technical signals with moving averages indicating selling pressure. The company remains pre-revenue with significant losses (-$244.17M net income in 2025) and negative cash flow from operations. Recent investor conference presentations highlight ongoing development of engineered cell therapies, though earnings have missed expectations in two of the last three quarters.
Despite analyst optimism (82% buy ratings), SANA faces substantial execution risk as a clinical-stage biotech with no current revenue and high cash burn. The stock's outlook depends heavily on clinical trial progress and future funding needs, with current valuation at 5.41x book value despite negative profitability metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Global Payments Inc
Global Payments is a leading provider of payment processing and software solutions and focuses on serving small and midsize merchants. The company operates in 30 countries and generates about one fourth of its revenue from outside North America, primarily in Europe and Asia. In 2019, Global Payments merged with Total System Services in an all-stock deal that gave Total System Services shareholders 48% of the combined company's shares.
Read more on GPN →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
